Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Share
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
Asian Stocks Eye Soft Start as Fed Doubts Simmer: Markets Wrap
Meet the Newest Addition to the S&P 500. The Stock Has Soared 845% Since Early Last Year, and It’s Still a Buy Right Now, According to 1 Wall Street Analyst.
Stock market today: Indexes tumble after Fed comments dent December rate-cut odds
Moderna Stock Is Top Performer in S&P 500 Tuesday After Miserable 2023. Why This Year Could Be Better.
Moderna stock was one of the worst performers in the S&P 500 last year as Covid-19 vaccine sales tumbled, but the vaccine maker has more to offer, according to Oppenheimer analysts.
Continue reading this article with a Barron’s subscription.
View Options
Source link
Asian Stocks Eye Soft Start as Fed Doubts Simmer: Markets Wrap
Meet the Newest Addition to the S&P 500. The Stock Has Soared 845% Since Early Last Year, and It’s Still a Buy Right Now, According to 1 Wall Street Analyst.
Stock market today: Indexes tumble after Fed comments dent December rate-cut odds
Stock market today: Indexes mixed as traders digest wholesale inflation and await Powell’s remarks